Journal
MEMORIAS DO INSTITUTO OSWALDO CRUZ
Volume 95, Issue 5, Pages 721-728Publisher
FUNDACO OSWALDO CRUZ
DOI: 10.1590/S0074-02762000000500020
Keywords
Plasmodium falciparum; malaria; dihydrofolate reductase; dihydropteroate synthase; drug resistance; Brazilian Amazon
Categories
Ask authors/readers for more resources
Since the late 1970s pyrimethamine-sulfadoxine (PS; Fansidar(TM) Hoffman-LaRoche, Basel) has been used as first line therapy for uncomplicated malaria in the Amazon basin. Unfortunately, resistance has developed over the last ten years in many; regions of the Amazon and PS is no longer recommenced for use in Brazil. In vitro resistance to pyrimethamine and cycloguanil (the active metabolite of proguanil) is caused by specific point mutations in Plasmodium falciparum dihydrofolate reductase (DHFR), and in vitro resistance to sulfadoxine has been associated with mutations in dihydropteroate synthase (DHPS). In association with a proguanil-sulfamethoxazole clinical trial in Brazil, we performed a nested mutation-specific polymerase chain reaction to measure prevalence of DHFR mutations at codons 50, 51, 59, 108 and 164 and DHPS mutations at codons 436, 437, 540, 581 and 613 at three sites in the Brazilian Amazon. Samples from two isolated towns showed a high degree of homogeneity, with the DHFR Arg-50/Ile-51/Asn-108 and DHPS Gly-437/Glu-540/Gly-581 mutant genotype accounting for all infections in Peixoto de Azevedo (n = 15) and 60% of infections in Apiacas (n = 10), State of Mato Grosso. The remaining infections in Apiacas differed from this predominant genotype only by the addition of the Bolivia repeat at codon 30 and the Leu-164 mutation in DHFR. By contrast, 17 samples from Porto Velho, capital city of the State of Rondonia, with much in- and out-migration, showed a wide variety of DHFR and DHFR genotypes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available